BRIDGEBIO PHARMA INC (BBIO)
US10806X1028 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 69.72M 745.09% | 77.65M 11.37% | 9.303M -88.02% | 223.92M 2,306.97% | 184.33M -17.68% | 416.2M 125.79% | 877.82M 110.91% | 1.586B 80.67% | 2.368B 49.31% | 3.041B 28.42% | 3.278B 7.79% | |
| EBITDA YoY % growth | -570.79M -19.16% | -461.66M 19.12% | -592.95M -28.44% | -566.807M 4.41% | -611.305M -7.85% | -418.375M 31.56% | -399.84M 4.43% | -2.04M 99.49% | 318.24M 15,700.00% | 641.58M 101.60% | 931.26M 45.15% | |
| EBIT YoY % growth | -576.63M -21.53% | -468.43M 18.76% | -599.444M -27.97% | -566.977M 5.42% | -661.671M -16.70% | -519.3M 21.52% | -326.57M 37.11% | 214.23M 165.60% | 915.41M 327.30% | 1.551B 69.43% | 1.462B -5.74% | |
| Operating Margin | -827.07% | -603.26% | -6,443.56% | -253.21% | -358.96% | -124.77% | -37.20% | 13.51% | 38.66% | 51.00% | 44.60% | |
| EPS YoY % growth | -3.91 -2.89% | -3.11 20.46% | -3.94 -26.69% | -2.67 32.14% | -3.77 -41.08% | -2.92 22.48% | -1.97 32.68% | 0.74 137.56% | 3.29 344.83% | 5.56 69.15% | 6.51 17.05% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.16 -21.29% | -0.98 -388.96% | -1.04 -166.44% | -1.02 7.27% | -0.94 19.28% | -0.99 -1.17% | -0.66 36.20% | -0.83 19.00% | -0.78 17.52% |
| Revenue Q2Q % growth | 3.197M 83.21% | 36.651M -82.64% | 30.42M 1,303.14% | 44.661M 1,534.74% | 61.892M 1,835.94% | 74.052M 102.05% | 139.23M 357.69% | 113.53M 154.20% | 129.23M 108.80% |
| EBITDA Q2Q % growth | 36.613M 121.52% | -140.597M -2,733.39% | -205.734M -21.39% | -164.026M 10.08% | -183.488M -601.15% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -158.207M 10.45% | -144.706M -3,966.04% | -169.956M 1.56% | -169.445M 9.45% | -173.52M -9.68% | -182.886M -26.38% | -124.644M 26.66% | -158.1M 6.70% | -149.328M 13.94% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -1.10 -1.85% | -1.00 | -0.10 | -10.20% |
| Q2 2024 Q2Q % growth | -0.39 60.20% | -1.09 | 0.70 | 64.07% |
| Q1 2024 Q2Q % growth | -0.20 78.26% | -0.78 | 0.58 | 74.34% |
| Q4 2023 Q2Q % growth | -0.96 -4.35% | -0.93 | -0.03 | -3.37% |
| Q3 2023 Q2Q % growth | -1.08 -16.13% | -0.83 | -0.25 | -29.83% |
| Q2 2023 Q2Q % growth | -0.98 -1,300.00% | -0.85 | -0.13 | -15.29% |
| Q1 2023 Q2Q % growth | -0.92 22.69% | -0.85 | -0.07 | -8.52% |
| Q4 2022 Q2Q % growth | -0.92 8.91% | -0.87 | -0.05 | -5.84% |
| Q3 2022 Q2Q % growth | -0.93 12.26% | -1.01 | 0.08 | 8.30% |
| Q2 2022 Q2Q % growth | -0.07 89.39% | -0.64 | 0.57 | 89.13% |
| Q1 2022 Q2Q % growth | -1.19 -0.85% | -1.13 | -0.06 | -5.11% |
| Q4 2021 Q2Q % growth | -1.01 | -0.89 | -0.12 | -14.11% |
| Q3 2021 Q2Q % growth | -1.06 -8.16% | -0.92 | -0.14 | -15.33% |
| Q2 2021 Q2Q % growth | -0.66 35.92% | -0.96 | 0.30 | 31.27% |
| Q1 2021 Q2Q % growth | -1.18 -51.28% | -0.75 | -0.43 | -56.60% |
| Q4 2020 Q2Q % growth | -1.01 -62.90% | -0.87 | -0.14 | -16.65% |
| Q3 2020 Q2Q % growth | -0.98 -92.16% | -0.94 | -0.04 | -4.43% |
| Q2 2020 Q2Q % growth | -1.03 70.23% | -0.79 | -0.24 | -30.80% |
| Q1 2020 Q2Q % growth | -0.78 | -0.68 | -0.10 | -13.89% |
| Q4 2019 Q2Q % growth | -0.62 | -0.71 | 0.09 | 12.81% |
| Q3 2019 Q2Q % growth | -0.51 | -0.56 | 0.05 | 9.37% |
| Q2 2019 Q2Q % growth | -3.46 | -0.53 | -2.93 | -557.76% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 2.732M -33.22% | 3.837M | -1.105M | -28.80% |
| Q2 2024 Q2Q % growth | 2.168M 32.11% | 3.641M | -1.473M | -40.46% |
| Q1 2024 Q2Q % growth | 211.12M 11,461.88% | 14.314M | 196.806M | 1,374.92% |
| Q4 2023 Q2Q % growth | 1.745M -6.68% | 6.353M | -4.608M | -72.53% |
| Q3 2023 Q2Q % growth | 4.091M 1,103.24% | 4.118M | -27K | -0.66% |
| Q2 2023 Q2Q % growth | 1.641M -97.77% | 3.053M | -1.412M | -46.25% |
| Q1 2023 Q2Q % growth | 1.826M 8.05% | 3.443M | -1.617M | -46.96% |
| Q4 2022 Q2Q % growth | 1.87M -85.49% | 4.615M | -2.745M | -59.48% |
| Q3 2022 Q2Q % growth | 340K -85.47% | 8.063M | -7.723M | -95.78% |
| Q2 2022 Q2Q % growth | 73.75M 36.52% | 16.389M | 57.361M | 350.00% |
| Q1 2022 Q2Q % growth | 1.69M 267.39% | 4.789M | -3.099M | -64.71% |
| Q4 2021 Q2Q % growth | 12.89M 10,641.67% | 22.009M | -9.119M | -41.43% |
| Q3 2021 Q2Q % growth | 2.34M -71.22% | 17.706M | -15.366M | -86.78% |
| Q2 2021 Q2Q % growth | 54.02M | 35.536M | 18.484M | 52.01% |
| Q1 2021 Q2Q % growth | 460K | 31.091M | -30.631M | -98.52% |
| Q4 2020 Q2Q % growth | 120K -99.13% | 17.269M | -17.149M | -99.31% |
| Q3 2020 Q2Q % growth | 8.13M -69.60% | 8.772M | -642K | -7.32% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -542.61% | -13.18% | -49.52% |
| Revenue | 0% | -98.63% | -12.43% | -42.42% |